Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Vaginal progesterone prophylaxis for preterm birth

In The Lancet, Jane Norman and colleagues (May 21, p 2106)1 reported the OPPTIMUM study, in which vaginal progesterone was not associated with a reduced risk of preterm birth or composite neonatal outcomes, and had no long-term benefit or harm on outcomes in children at age 2 years.2 These results are in contrast to the Cochrane Library meta-analysis reporting that progestogens reduced the incidence of preterm birth.3 Norman and colleagues commented that their findings suggest that the efficacy of progesterone in improving outcomes is either non-existent or weak.